Home › Korean Stocks › Quratis

Quratis signs USD 1.87m clinical drug supply contract with Access to Advanced Health (UK)

Quratis (큐라티스) · KOSDAQ 348080 · Single sales/supply contract · Filed 2026-11-20 · Summary published 2026-11-21

For reference only, not investment advice.This is a factual summary of a company filing. It is not a recommendation to buy, sell or hold any security. Read the original filing on DART before making any decision. Full disclaimer

What was filed

Quratis disclosed a contract to supply clinical-trial pharmaceuticals to Access to Advanced Health (UK) Ltd, a vaccine technology developer.

Key facts

Contract amountUSD 1,870,000 (KRW 2.49 billion at KRW 1,331.10/USD)
Share of recent revenue101.31% of 2025 separate revenue (KRW 2.46 billion)
CounterpartyAccess to Advanced Health (UK) Ltd, a London subsidiary of the US-based AAHI, set up in 2025
Term19 Nov 2026 to 30 Jun 2030
Payment termsNo advance; paid on acceptance of five milestones (contract / technical feasibility, process development/GMP production, preliminary stability, CMC documents, stability)

Context

Payment is tied to milestone deliverables over about three and a half years rather than paid upfront.

Original filing: DART receipt no. 20261120900789 (Korean)

Figures are taken from the filing as submitted. KRW conversions use the exchange rate stated in the filing. Filings can be corrected later; the DART version prevails.